SCHEMBL13234331

SCHEMBL13234331

Cc1ccnc(CCNc2ccc3ncc(-c4ccc(F)c(Cl)c4)n3n2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 6/20 0.52
FYN P06241 14/20 0.48
CCNT1 O60563 1/20 0.44
ABL1 P00519 1/20 0.44
PGK1 P00558 1/20 0.44
CDK1 P06493 1/20 0.44
PIM1 P11309 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
CSNK1E P49674 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CDK9 P50750 1/20 0.44
JAK3 P52333 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
HASPIN Q8TF76 1/20 0.44
AURKB Q96GD4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13234311 0.92 MKNK1 (0.55) MKNK1FYNCCNT1ABL1PGK1
SCHEMBL13234322 0.88 MKNK1 (0.52) MKNK1FYNCCNT1ABL1PGK1
SCHEMBL13234327 0.87 MKNK1 (0.54) MKNK1FYNPIM1
SCHEMBL2948690 0.87 MKNK1 (0.71) MKNK1FYNPIM1
SCHEMBL13234329 0.87 MKNK1 (0.59) MKNK1FYNCCNT1PIM1CCNA2
SCHEMBL13234314 0.83 MKNK1 (0.59) MKNK1FYNCCNT1ABL1PGK1
SCHEMBL2949676 0.80 PIM1 (0.65) MKNK1FYNPIM1
SCHEMBL2943842 0.80 MKNK1 (0.72) MKNK1FYN
SCHEMBL2950588 0.79 FYN (0.67) MKNK1FYNABL1PIM1
SCHEMBL13234321 0.79 MKNK1 (0.53) MKNK1FYNCCNT1ABL1PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
WO-2007025540-A2 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 MKNK1 144/4885FYN 421/4885CCNT1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.